Tag Archives | pharmacogenomics

Biotech Wreck: What To Look For Next

Biotech Wreck Is Sobering For Bulls Political Impact Of Drug Pricing Could Be Lasting Through 2020 Long Term Trends Intact demographics and M&A Biotech was collateral damage from the surprising and sudden realization that the politics of drug pricing is here to stay and healthcare will be a 2020 Election issue. The clues to this […]

Continue Reading 0

Choppy Week in Healthcare with Drug Pricing Issues Yet Again: Update-2-SELL-OFF

Update-2 10:45a 4/17…XBI down 3.37% to FEB support at $86.  Healthcare issues are spilling over to biotech.Red screen day and all biotechs hit very hard.Drug pricing models are under scrutiny. Update-1…NASDAQ ekes out small gains but large cap biotechs take another hit with IBB down 1% to $109.39. All large caps in the red: REGN […]

Continue Reading 0

Biotech Stocks catch a Second Wind Helped by Tech Stocks…Update-4

ALERT 3/21/19…BIOGEN (BIIB) down 28% to $233 after dropping Alzheimer’s Disease late stage trial; another failed clinical stage drug in AD. (more later). IBB down 2.5%. ====== 3/20/19…a whipsaw day…Powell comes to market rescue with “economy is growing at a solid pace” and leaving rates unchanged (patience); but Trump says earlier that he will keep […]

Continue Reading 0

Small Cap Biotechs Lead the Market in 2019 Up 20% YTD…GNMK, ONCE, XBI-Updates

Update: 1:40 EST 2/25… Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%. Another big deal as GE sells healthcare business to Danher (DHR) for $21.4B; GE up 8.26%, DHR up 8.38%. ========== M&A Drives Mid and Small Cap Biotechs Stocks Higher The Small Cap weighted XBI is up […]

Continue Reading 0

Emerging Growth Stocks: Long Ideas in Life Science for 2019…Updates-Risk On…FED on Hold and “Patient”

Update ….Jan 30 2:45p  EST …FED to be Patient and Policy Stance is Appropriate FED to “wait and see” before raising rates-stocks soar. FED-“US Economy in a good place” NASDAQ up 2%, DOW up 1.73%, S&P up 1.53% XLV up 1.27%, IBB flat, XBI up 1.72%. Large cap biopharmas trail broad rally: AMGN,BIIB in the […]

Continue Reading 0

Large Cap Biopharmaceutical Performance 2018…Updates BMY CELG, XBI

1/7/19 After Close: Both BMY and CELG held today up over 3%. ==== Stay tuned Next Week for Updates from the J.P.Morgan Healthcare Conference 1/5/19 Friday’s broad-based biopharmaceutical rally boosts stocks out of a “Bear Market”which brought the XBI down 25% off highs to the  $64 level on December 24, 2018 and now at $75. […]

Continue Reading 0

Trading the Biotech Bottom in 2018 in an Ambivalent Market…Updates ASH TSRO XBI

Update-2 December 3 …Our Top Pick TSRO is up 58% on GSK Buyout We recommended Tesaro (TSRO) at $34 and it paid off today with a ~$5.1B buyout by GlaxoSmith Kline! Year End Rally Intact with XBI up over 3% to $84 handle, ====== Update-1 December 1… NASDAQ Rallies 0.79% on Nov 30 Our recent […]

Continue Reading 0

Biotech Bear Market: But It Is Time to Start Trading…11/9 Updates on Rally

Update at Close 11/9/18 Remain Cautious as Rally Fails The NASDAQ down 1.6% and Russell 2000 down 1.8%, sold off killing hopes of a continued Post-Election rally. The biotech sector is for experienced traders only. The healthcare still looks good overall with the XLV down only 0.29% at $92.95. The XBI was crushed again down […]

Continue Reading 0

Biotech Momentum Lost Mired in Macro-Economic News Cycle: China, FED,Trade etc.

Biotech Momentum Lost Technical Breakdown: XBI Near April Bottom but XLV Looks Good Market Looking for Growth from Large Cap Earnings 10 year auction has tepid demand at Yield of 3.225%, NASDAQ at 7602 own 1.75% (Prices as of mid-day 1:30 p EDT) Biotech momentum losses were triggered by a reversal in investor psychology  because […]

Continue Reading 0

Rayno BioBeat #6: Biotech Sell-Off with Broad Market Concerns…Updates

Update 10/5/18 Very Weak Technicals after Biotech Sell-Off NASDAQ market closed off the lows down 1.16% at 7788. Biotech ETF IBB down 1.15% just above 3 month support of 116. Biotech ETF XBI down 1.51% at 90.45 broke downtrend line and May support at 92. More losers again but a several winners: e.g. BLUE,CRSP,IONS,RHHBY. Our […]

Continue Reading 0